This review discusses evidence in support of the use of Abilify Maintena (aripiprazole long acting injection; aripiprazole LAI) for maintenance of clinical improvement in the treatment of schizophrenia. Abilify Maintena is licensed in New Zealand, and is fully subsidised by PHARMAC for this use (with Special Authority criteria).
This publication has been commissioned and funded by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Ltd. The content is based on published studies and the author’s opinions and may not reflect the views of Lundbeck or Otsuka. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. All trademarks mentioned in this review are the property of their respective owners.
Please login below to download this issue (PDF)